US 11,987,625 B2
Anti-CD300F antibody and uses thereof
Derek Nigel John Hart, New South Wales (AU); Georgina Jane Clark, New South Wales (AU); and Robin Gasiorowski, New South Wales (AU)
Assigned to DENDROCYTE BIOTECH PTY LTD, New South Wales (AU)
Appl. No. 16/462,688
Filed by DENDROCYTE BIOTECH PTY LTD, Balmain (AU)
PCT Filed Nov. 22, 2017, PCT No. PCT/AU2017/051288
§ 371(c)(1), (2) Date May 21, 2019,
PCT Pub. No. WO2018/094460, PCT Pub. Date May 31, 2018.
Claims priority of application No. 2016904779 (AU), filed on Nov. 22, 2016.
Prior Publication US 2023/0063312 A1, Mar. 2, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/02 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/02 (2018.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. An isolated antibody, or antigen binding fragment thereof, which specifically binds to an extracellular domain of CD300f, wherein the antibody, or antigen binding fragment thereof, comprises; (a) a heavy chain variable region comprising a complementarity determining region 1 (CDR1) that comprises the amino acid sequence of SEQ ID NO: 2, a complementarity determining region 2 (CDR2) that comprises the amino acid sequence of SEQ ID NO: 3, and a complementarity determining region 3 (CDR3) that comprises the amino acid sequence of SEQ ID NO: 4; and (b) a light chain variable region comprising a complementarity determining region 1 (CDR1) that comprises the amino acid sequence of SEQ ID NO: 6, a complementarity determining region 2 (CDR2) that comprises the amino acid sequence of SEQ ID NO: 7, and a complementarity determining region 3 (CDR3) that comprises the amino acid sequence of SEQ ID NO: 8.